Polycythemia Market Report 2026

The polycythemia market size has grown strongly in recent years. It will grow from $4.68 billion in 2025 to $4.99 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising prevalence of myeloproliferative disorders, increasing awareness of rare blood diseases, expansion of specialty hematology centers, higher diagnostic testing rates, growth in use of cytoreductive drugs.

The polycythemia market size is expected to see strong growth in the next few years. It will grow to $6.53 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to advancements in targeted JAK2 therapies, increasing genetic screening adoption, rising demand for personalized treatment plans, expanding access to specialty biologics, growing elderly population base. Major trends in the forecast period include growing adoption of janus kinase inhibitors, rising use of interferon based injectable therapies, increasing preference for therapeutic phlebotomy procedures, expansion of hematocrit monitoring diagnostics, shift toward combination drug therapy approaches.

The increasing prevalence of myeloproliferative diseases is expected to drive the growth of the polycythemia market in the coming years. Myeloproliferative diseases encompass a group of rare blood disorders marked by the abnormal overproduction of blood cells in the bone marrow, impairing blood function and circulation. The rising occurrence of age-related hematological abnormalities is a major contributor to the increased prevalence of these disorders, as older populations are more vulnerable to bone marrow dysfunction. Polycythemia, a significant subtype of myeloproliferative diseases characterized by excessive red blood cell production, plays a crucial role in enhancing clinical awareness, diagnosis, and ongoing monitoring of these conditions, thereby supporting market growth. For instance, in September 2024, according to Blood Cancer United, a US-based nonprofit organization focused on curing blood cancers, over 120,000 people in the United States were estimated to be living with or in remission from myeloproliferative neoplasms (MPNs) in 2023, indicating a rising prevalence of these chronic hematologic disorders. Therefore, the growing incidence of myeloproliferative diseases is driving the polycythemia market.

Key companies operating in the polycythemia market are focusing on advanced innovations such as rusfertide, a first-in-class hepcidin mimetic peptide, which significantly reduces the need for frequent phlebotomies while improving hematocrit control and patient quality of life. A hepcidin mimetic is a drug or compound designed to act like hepcidin, the body’s main hormone that regulates iron balance. For example, in March 2025, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical company, announced positive topline results from the Phase 3 VERIFY study of rusfertide in patients with polycythemia vera, demonstrating significant reduction in phlebotomy dependence, improved hematocrit control, and meaningful patient-reported outcomes, while maintaining a favorable safety profile.

In March 2025, Ono Pharmaceutical, a Japan-based pharmaceutical company, partnered with Ionis Pharmaceuticals to advance the development, regulatory approval, and global commercialization of sapablursen, a novel RNA-targeted therapy for polycythemia vera, leveraging Ionis Pharmaceuticals’ expertise to address unmet needs in rare blood disorders. Ionis Pharmaceuticals is a US-based company specializing in RNA-targeted therapies for rare blood disorders, including treatments for polycythemia.

Major companies operating in the polycythemia market are Bristol Myers Squibb Company, Roche Holding AG, Merck And Company Inc., Bayer AG, Novartis AG, Takeda Pharmaceutical Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Incyte Corporation, Ionis Pharmaceuticals Inc., CTI BioPharma Corp., AOP Orphan Pharmaceuticals AG, Silence Therapeutics Plc, Italfarmaco S.p.A., PharmaEssentia Corporation, Karyopharm Therapeutics Inc., Protagonist Therapeutics Inc., Kartos Therapeutics Inc., Geron Corporation, and Perseus Proteomics Inc.

Tariffs are influencing the polycythemia market by increasing the import cost of active pharmaceutical ingredients, biologic injectables, and hematology diagnostic kits used across treatment workflows. These duties are raising production and procurement expenses for manufacturers that depend on cross border sourcing of drug compounds and medical consumables. Drug classes such as jak inhibitors and interferon products are more exposed due to complex global supply chains. North america and parts of europe face stronger impact where specialty drugs are frequently imported. Smaller suppliers and hospital procurement networks are experiencing margin pressure and slower purchasing cycles. At the same time, tariff barriers are encouraging domestic manufacturing of hematology drugs and phlebotomy kits. This is supporting local suppliers and improving regional supply chain stability.

The polycythemia market research report is one of a series of new reports that provides polycythemia market statistics, including polycythemia industry global market size, regional shares, competitors with a polycythemia market share, detailed polycythemia market segments, market trends and opportunities, and any further data you may need to thrive in the polycythemia industry. This polycythemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Polycythemia refers to a blood disorder in which the body generates an abnormally elevated number of red blood cells, leading to increased blood viscosity and reduced efficiency of blood flow. This disorder can result in complications such as blood clots, strokes, and cardiovascular issues, and it may arise as a primary bone marrow condition or secondarily due to low oxygen levels or other underlying medical problems.

The major types of polycythemia include primary polycythemia, secondary polycythemia, and pseudopolycythemia. Primary polycythemia is a blood disorder marked by the overproduction of red blood cells due to intrinsic bone marrow abnormalities. Treatments are classified by drug classes, including antimetabolites, Janus kinase 2 inhibitors, myelosuppressive agents, selective serotonin reuptake inhibitors, folic acid, and other categories, administered through oral, intravenous, and intramuscular routes. End users include hospital pharmacies, retail pharmacies, and online pharmacies.

The polycythemia market consists of sales of therapeutic phlebotomy kits, cytoreductive drug formulations, antiplatelet medication products, janus kinase inhibitor drugs, interferon-based injectable products, and hematocrit monitoring test kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.